Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Cymbalta
Active Ingredient: Duloxetine hydrochloride 33.7mg equivalent to duloxetine base 30mg
Dosage Form: Modified release capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Eli Lilly and Co, Lilly Technology Centre, Indianapolis, Indiana, United States of America
Product: Cymbalta
Active Ingredient: Duloxetine hydrochloride 67.3mg equivalent to duloxetine base 60mg
Dosage Form: Modified release capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Eli Lilly and Co, Lilly Technology Centre, Indianapolis, Indiana, United States of America
Product: Hexal Ranitidine Forte
Active Ingredient: Ranitidine hydrochloride 336mg equivalent to ranitidine 300mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Salutas Pharma GmbH, Barleben, Germany
Product: Pfizer Ranitidine 24 Hour Action
Active Ingredient: Ranitidine hydrochloride 336mg equivalent to ranitidine 300mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Salutas Pharma GmbH, Barleben, Germany
Product: Sumatriptan
Active Ingredient: Sumatriptan succinate 140mg equivalent to 100mg sumatriptan
Dosage Form: Film coated tablet
New Zealand Sponsor: REX Medical Limited
Manufacturer: Cipla Limited, Manufacturing Division, Verna Industrial Area, Salcette Goa, India
Product: Sumatriptan
Active Ingredient: Sumatriptan succinate 70mg equivalent to 50mg sumatriptan
Dosage Form: Film coated tablet
New Zealand Sponsor: REX Medical Limited
Manufacturer: Cipla Limited, Manufacturing Division, Verna Industrial Area, Salcette Goa, India
Dated this 13th day of December 2007.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).